Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus Target Price from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $93.33.

PBH has been the subject of a number of research reports. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th.

Prestige Consumer Healthcare Trading Up 0.6%

Shares of PBH traded up $0.49 during midday trading on Tuesday, hitting $76.77. The stock had a trading volume of 429,530 shares, compared to its average volume of 428,423. Prestige Consumer Healthcare has a fifty-two week low of $64.94 and a fifty-two week high of $90.04. The business has a 50-day simple moving average of $81.81 and a two-hundred day simple moving average of $82.26. The firm has a market cap of $3.79 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 2.29 and a beta of 0.43. The company has a current ratio of 4.20, a quick ratio of 2.82 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. Prestige Consumer Healthcare's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently made changes to their positions in the business. Envestnet Portfolio Solutions Inc. purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $291,000. Corient Private Wealth LLC grew its stake in shares of Prestige Consumer Healthcare by 331.6% during the fourth quarter. Corient Private Wealth LLC now owns 15,163 shares of the company's stock valued at $1,184,000 after buying an additional 11,650 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $362,000. Xponance Inc. grew its stake in shares of Prestige Consumer Healthcare by 10.1% during the fourth quarter. Xponance Inc. now owns 3,570 shares of the company's stock valued at $279,000 after buying an additional 328 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Prestige Consumer Healthcare by 17.9% during the fourth quarter. Teacher Retirement System of Texas now owns 14,682 shares of the company's stock valued at $1,147,000 after buying an additional 2,224 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.